Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection

被引:89
作者
Chu, Jang-Hann J. [1 ]
Chiang, Cern-Cher S. [1 ]
Ng, Mah-Lee [1 ]
机构
[1] Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, Singapore 117597, Singapore
关键词
D O I
10.4049/jimmunol.178.5.2699
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The domain III of the West Nile virus (WNV) envelope glycoprotein (E) was shown to serve as virus attachment domain to the cellular receptor, and neutralizing Abs have been mapped to this specific domain. In this study, domain III of the WNV E protein (WNV E DIII) was expressed as a recombinant protein and its potential as a subunit vaccine candidate was evaluated in BALB/C mice. Immunization of WNV E DIII protein with oligodeoxynucleotides (CpG-DNA) adjuvant by i.p. injection was conducted over a period of 3 wk. The immunized mice generated high titer of WNV-neutralizing Abs. Marine Ab against WNV E DIII protein was also capable of neutralizing Japanese encephalitis virus. The IgG isotypes generated were predominantly IgG2a in the murine sera against the recombinant protein. Splenocyte cultures from the mice coadministrated with WNV E DIII protein and CpG secreted large amounts of iFN-gamma and IL-2 and showed proliferation of T cells in the presence of WNV E Dill protein. Overall, this study highlighted that recombinant WNV E DIII protein delivered in combination with CpG adjuvant to mice generated a Th1 immune response type against WNV and can serve as a potential vaccine to prevent WNV infection.
引用
收藏
页码:2699 / 2705
页数:7
相关论文
共 24 条
[1]   Manipulation of cell surface macromolecules by flaviviruses [J].
Anderson, R .
FLAVIVIRUSES: STRUCTURE, REPLICATION AND EVOLUTION, 2003, 59 :229-+
[2]  
[Anonymous], ARCH VIROL S18
[3]   ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy [J].
Arroyo, J ;
Miller, C ;
Catalan, J ;
Myers, GA ;
Ratterree, MS ;
Trent, DW ;
Monath, TP .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12497-12507
[4]   Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein [J].
Beasley, DWC ;
Barrett, ADT .
JOURNAL OF VIROLOGY, 2002, 76 (24) :13097-13100
[5]   Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein [J].
Bhardwaj, S ;
Holbrook, M ;
Shope, RE ;
Barrett, ADT ;
Watowich, SJ .
JOURNAL OF VIROLOGY, 2001, 75 (08) :4002-4007
[6]  
*CDC, 2005, MMWR-MORBID MORTAL W, V54, P1253
[7]   Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein [J].
Chu, JJH ;
Rajamanonmani, R ;
Li, J ;
Bhuvanakantham, R ;
Lescar, J ;
Ng, ML .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :405-412
[8]   Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway [J].
Chu, JJH ;
Ng, ML .
JOURNAL OF VIROLOGY, 2004, 78 (19) :10543-10555
[9]   West Nile Virus in the United States (1999-2005) [J].
Gerhardt, Reid .
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 2006, 42 (03) :170-177
[10]   Epidemiology and transmission dynamics of West Nile Virus disease [J].
Hayes, EB ;
Komar, N ;
Nasci, RS ;
Montgomery, SP ;
O'Leary, DR ;
Campbell, GL .
EMERGING INFECTIOUS DISEASES, 2005, 11 (08) :1167-1173